Ponsegromab for the Treatment of Cancer Cachexia.
John D GroarkeJeffrey CrawfordSusie M CollinsShannon LubaczewskiEric J RoelandTateaki NaitoAndrew E HendifarMarie FallonKoichi TakayamaTimothy AsmisRichard F DunneIsik KarahanogluCarrie A NorthcottMagdalena A HarringtonMichelle RossulekRuolun QiuAditi R SaxenaPublished in: The New England journal of medicine (2024)
Among patients with cancer cachexia and elevated GDF-15 levels, the inhibition of GDF-15 with ponsegromab resulted in increased weight gain and overall activity level and reduced cachexia symptoms, findings that confirmed the role of GDF-15 as a driver of cachexia. (Funded by Pfizer; ClinicalTrials.gov number, NCT05546476.).